Abstract

Biologic Therapies in Ankylosing Spondylitis: Efficacy and Safety Profile

Author(s): Noah King*

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints. It often leads to progressive spinal fusion and severe disability if left untreated. Biologic therapies, particularly tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) inhibitors, have revolutionized the treatment landscape of AS. This article reviews the efficacy and safety of these biologic therapies and explores emerging treatment strategies for patients who do not respond to standard biologic treatments.